In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MTI 100: Medtech Giants Trade Places

Executive Summary

The global medtech industry has a new leader, after a bulked-up Medtronic bumped Johnson & Johnson from first place. But astute M&A deals, as well as divestments and impact from poor sales and negative currency effects, have also led to other movements in the medtech rankings, according to Medtech Insight's annual review at the top medical device companies.

You may also be interested in...



Medtechs At The Wheel In New Health Care Landscape

2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.

MTI 100: The Rise And Fall Of Medtech's Giants

The global medtech industry has a new leader, after a bulked-up Medtronic knocked Johnson & Johnson off its throne. But astute M&A deals, as well as divestments and knock-on impact from poor sales and negative currency effects, have also led to other movements in the medtech company rankings. Medtech Insight's 2016 edition of its annual league tables – MTI 100 and the Top 10 sector leaders – show who's climbed up and who's slipped down.

M&A Analysis: November Deal Making Hits Whole New Low

M&A deal activity dropped dramatically in November with a mere six deals in the medtech industry, making November the weakest month of the year so far. The biggest deal of the month recorded was Edward Lifesciences $690m acquisition of Israeli start-up Valtech.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel